Paper41900829
Self-Assembled Gefitinib Nanosuspension Prepared via Hummer Acoustic Resonance Technology: Enhanced Dissolution, In Vitro Anticancer Activity and Long-Term Stability.
Wu HL and 9 others. Pharmaceutics, 2026. Cited by 1 paper, by iCite.
Cite this record
ConductScience Library. Self-Assembled Gefitinib Nanosuspension Prepared via Hummer Acoustic Resonance Technology: Enhanced Dissolution, In Vitro Anticancer Activity and Long-Term Stability. Papers, record 41900829. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41900829
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Self-Assembled Gefitinib Nanosuspension Prepared via Hummer Acoustic Resonance Technology: Enhanced Dissolution, In Vitro Anticancer Activity and Long-Term Stability.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Grants4
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| 22161009 | National Natural Science Foundation of China | PubMed | ||
| 2025GXNFAA069355 | Guangxi Science and Technology Program | PubMed | ||
| 202408 | Guangxi University of Chinese Medicine "Qihuang Project" High-level Talent Team Cul-tivation Programme | PubMed | ||
| 2022C014 | Gui Style Xinglin Top Talent Funding Project of Guangxi University of Chinese Medicine | PubMed |
Source PubMed
References30
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 39817679 | Cancer statistics, 2025. | CA Cancer J Clin | 2025 | https://conductscience.org/library/papers/39817679 | PubMed |
| 2 | 32243963 | Development and evaluation of TPGS/PVA-based nanosuspension for enhancing dissolution and oral bioavailability of ticagrelor. | Int J Pharm | 2020 | https://conductscience.org/library/papers/32243963 | PubMed |
| 3 | 39861782 | Nanosuspension Innovations: Expanding Horizons in Drug Delivery Techniques. | Pharmaceutics | 2025 | https://conductscience.org/library/papers/39861782 | PubMed |
| 4 | 31969986 | Emerging role of nanosuspensions in drug delivery systems. | Biomater Res | 2020 | https://conductscience.org/library/papers/31969986 | PubMed |
| 5 | 37567370 | The first nano-cocrystal formulation of marine drug cytarabine with uracil based on cocrystal nanonization strategy for long-acting injection exhibiting enhanced antitumor activity. | Int J Pharm | 2023 | https://conductscience.org/library/papers/37567370 | PubMed |
| 6 | 39930276 | Unveiling the Potential of Nanosuspension Formulation Strategy for Improved Oral Bioavailability of Gefitinib. | AAPS PharmSciTech | 2025 | https://conductscience.org/library/papers/39930276 | PubMed |
| 7 | 37765182 | Do Mixtures of Beads with Different Sizes Improve Wet Stirred Media Milling of Drug Suspensions? | Pharmaceutics | 2023 | https://conductscience.org/library/papers/37765182 | PubMed |
| 8 | 22160570 | Synergistic inhibitory effects by the combination of gefitinib and genistein on NSCLC with acquired drug-resistance in vitro and in vivo. | Mol Biol Rep | 2012 | https://conductscience.org/library/papers/22160570 | PubMed |
| 9 | 39953594 | Carrier-free nanoparticles-new strategy of improving druggability of natural products. | J Nanobiotechnology | 2025 | https://conductscience.org/library/papers/39953594 | PubMed |
| 10 | 23954372 | Stability of nanosuspensions in drug delivery. | J Control Release | 2013 | https://conductscience.org/library/papers/23954372 | PubMed |
| 11 | 39477136 | Spring and parachute approach for piroxicam dissolution; its phenomenological model on the thermodynamics of irreversible processes. | Int J Pharm | 2024 | https://conductscience.org/library/papers/39477136 | PubMed |
| 12 | 34984564 | Solid Dispersions of Gefitinib Prepared by Spray Drying with Improved Mucoadhesive and Drug Dissolution Properties. | AAPS PharmSciTech | 2022 | https://conductscience.org/library/papers/34984564 | PubMed |
| 13 | 37627812 | Systematic Screening Study for the Selection of Proper Stabilizers to Produce Physically Stable Canagliflozin Nanosuspension by Wet Milling Method. | Bioengineering (Basel) | 2023 | https://conductscience.org/library/papers/37627812 | PubMed |
| 14 | 28315464 | A novel nanosuspension of andrographolide: Preparation, characterization and passive liver target evaluation in rats. | Eur J Pharm Sci | 2017 | https://conductscience.org/library/papers/28315464 | PubMed |
| 15 | 37242763 | Formulation Strategies of Nanosuspensions for Various Administration Routes. | Pharmaceutics | 2023 | https://conductscience.org/library/papers/37242763 | PubMed |
| 16 | 20600732 | Miconazole nanosuspensions: Influence of formulation variables on particle size reduction and physical stability. | Int J Pharm | 2010 | https://conductscience.org/library/papers/20600732 | PubMed |
| 17 | 38168678 | Delivery of gefitinib loaded nanoparticles for effectively inhibiting prostate cancer progression. | Biomater Sci | 2024 | https://conductscience.org/library/papers/38168678 | PubMed |
| 18 | 36436741 | Highly water-soluble dapsone nanocrystals: Towards innovative preparations for an undermined drug. | Int J Pharm | 2023 | https://conductscience.org/library/papers/36436741 | PubMed |
| 19 | 39586510 | Preparation and characterization of andrographolide nano-cocrystals using hummer acoustic resonance technology. | Int J Pharm | 2025 | https://conductscience.org/library/papers/39586510 | PubMed |
| 20 | 39370058 | Acoustic resonance technology and quality by design approach facilitate the development of the robust tetrandrine nano-delivery system. | Eur J Pharm Biopharm | 2024 | https://conductscience.org/library/papers/39370058 | PubMed |
Cited by1
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1 citation.
| PMID | Title | Journal | Year | In Papers |
|---|---|---|---|---|
| 42198266 | Development and In Vitro Evaluation of Gefitinib-Salicylic Acid Nanocrystals for Improved Bioavailability. | Pharmaceutics | 2026 | https://conductscience.org/library/papers/42198266 |
Source PubMed
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| EGFR | 1956 | PubTator's text mining | https://conductscience.org/library/genes/1956 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41900829
GET https://conductscience.org/api/papers/v1/41900829/references?page=2